<div id="readability-page-1"><div> <p>By Josh Beckerman</p> <pre></pre> <p>   Novavax shares declined right after The Wall Street Journal reported that the Food and Drug Administration is unlikely to give full approval soon for a company Covid-19 vaccine, but then the stock recovered. </p> <p>   Shares went as low as $5.70. They recently traded at $6.20, up 3.2%. </p> <p>   The vaccine is approved for emergency use. The FDA had set an April 1 deadline for a decision on whether to grant a normal, full approval, the WSJ reported. </p> <pre></pre> <p>   Write to josh.beckerman@wsj.com </p> <pre></pre> <p>   (END) Dow Jones Newswires</p> <p>   April 02, 2025 13:06 ET (17:06 GMT)</p><p>Copyright (c) 2025 Dow Jones &amp; Company, Inc.</p></div></div>

NVAX

<p>Novavax shares initially fell after a WSJ report indicated that the FDA is unlikely to grant full approval for its Covid-19 vaccine soon. The stock dropped to $5.70 but later recovered to $6.20, reflecting a 3.2% increase. The vaccine currently has emergency use approval, with the FDA's decision deadline set for April 1.</p>

Novavax Falls But Then Recovers After WSJ Report on Vaccine's FDA Status